PTC/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MEDICAL STATE	stitute for form 1449A/B/P1	ro		Complete if Known		
- 500	sudio for form 14-3/4007			Application Number	10/735461-Conf. #3119	
IN	<b>IFORMATION</b>	N DI	SCLOSURE	Filing Date	December 11, 2003	
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Michael P. CZECH	
				Art Unit	1635	
	(Use as many sh	eets as	necessary)	Examiner Name	J. B. Ashern	
Sheet	1	of	1	Attorney Docket Number	UMY-055	

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
DR.	A1*	US-5,958,773	09-28-1999	Monia et al.			
	A2*	US-20030084471-A1	05-01-2003	Beach et al.			
	A3*	US-20030157514-A1	08-21-2003	Finger et al.			
75	A4*	US-20030228597-A1	12-11-2003	Cowsert et al.			

	FOREIGN PATENT DOCUMENTS						
Evenine	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Examiner Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		
		-					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 90.04. \*Tener Office that Issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*8 Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
725	C1	Glasspool-Malone, Jill, et al., "Efficient Nonviral Cutaneous Transfection," Molecular Therapy, Vol. 2(2):140-146 (2000)				
RS	C2	Spiller, David G., et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood, Vol.</i> 91(12):4738-4746 (1998)				
RS	C3	Gehl, J., "Electroporation: theory and methods, perspectives for drug delivery, gene therapy adn research," <i>Acta Physiol Scand, Vol.</i> 177:437-447 (2003)				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	fare	Date Considered	6/8/06
	7		

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espand to a collection of information unless it contains a well-d 04/2 account.

Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 1 of

	Complete if Known
Application Number	10/735461-Conf. #3119
Filing Date	December 11, 2003
First Named Inventor	Michael P. CZECH
Art Unit	1635
Examiner Name	J.B. Ashen
Attorney Docket Number	UMY-055

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	[	-			-		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagas, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
						┢	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspig.gov">www.uspig.gov</a> or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>2</sup>
K	C1	Alessi, Dario, et al., "3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase," Current Biology, Vol. 7:776-789 (1997)	
	C2	Brazil, Derek P., et al., "Ten years of protein kinase B signalling: a hard Akt to follow," <i>Trends in Biochemical Sciences, Vol.</i> 26(11):657-664 (2001)	
	cs	Brummelkamp, Thijn R., et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," Science, Vol. 296:550-553 (2002)	
	ð	Calegari, Federica, et al., "Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA," PNAS, Vol. 99(22):14236-14240 (2002)	
	C5	Calera, Monica R., et al., "Insulin Increases the Association of Akt-2 with Glut4-containing Vesicles," The Journal of Biological Chemistry, Vol. 273(13):7201-7204 (1998)	
	C6	Chiu, Ya-Lin, et al., "RNAI in Human Cells: Basic Structural and Functional Features of Small Interfering RNA," Molecular Cell, Vol. 10:549-561 (2002)	
	C7	Cho, Han, et al., "Akt1/PKBα Is Required for Normal Growth but dispensable for Maintenance of Glucose Homeostasis in Mice," The Journal of Biological Chemistry, Vol. 276(42):38349-38352 (2001)	
	C8	Cho, Han, et al., "Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)," Science, Vol. 292:1728-1731 (2001)	
	C9	Cohen, Philip, et al., "The renaissance of GSK3," Molecular Cell Biology, Vol. 2:769-776 (2001)	
	C10	Cross, Darren A.E., et al., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kniase B," Nature, Vol. 378:785-789 (1995)	
	C11	Elbashir, Sayda M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , Vol. 411:494-498 (2001)	
	C12	Harrison, Scott A., et al., "Insulin Regulation of Hexose Transport in Mouse 3T3-L1 Cells Expressing the Human HepG2 Glucose Transporter," <i>The Journal of Biological Chemistry</i> , Vol. 265(33):20106-20116 (1990)	
	C13	Hill, Michelle M., et al., "A Role for Protein Kinase BB/Akt2 in Insulin-Stimulated GLUT4 Translocation in Adipocytes," Molecular and Cellular Biology, Vol. 19(11):7771-7781 (1999)	
/ls	C14	Kohn, Aimee D., et al., "Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation," The Journal of Biological Chemistry, Vol. 271(49):31372-31378 (1998)	

		/ \		
Examiner Signature		1	Date Considered	4406
	lacksquare			

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Suit	NFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete If Known			
				Application Number	10/735461-Conf. #3119	
11	IFORMATION	I DI	SCLOSURE	Filing Date	December 11, 2003	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Michael P. CZECH	
				Art Unit	1635	
	(Use as many sho	eets as	necessary)	Examiner Name	J.B. Ashen	
Sheet	2	of	2	Attorney Docket Number	UMY-055	

B	C15	Kotani, Ko, et al., "Requirement of Atypical Protein Kinase Cλ for Insulin Stimulation of Glucose Uptake but Not for Akt Activation in 3T3-L1 Adipocytes," <i>Molecular and Cellular Biology, Vol.</i> 18(12):6971-6982 (1998)	
1	C16	Lee, Nan Sook, et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells," nature biotechnology, Vol. 19:500-505 (2002)	
	C17	Lewis, David L., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," nature genetics, Vol. 32:107-108 (2002)	
	C18	McManus, Michael T., "Gene silencing using micro-RNA designed hairpins," RNA, Vol. 8:842-850 (2002)	
	C19	Miyagishi, Makoto, et al., "U6 promoter-driven siRNAs with four unidine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," nature biotechnology, Vol. 19:497-500 (2002)	
	C20	Okabe, Masataka, et al., "Translational repression determines a neuronal potential in Drosophila asymmetric cell division," Nature, Vol. 411:94-98 (2001)	
	C21	Paddison, Patrick J., et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalina cells," Genes & Development, Vol. 16:948-958 (2002)	
	C22	Paul, Cynthia P., et al., "Effective expression of small interfering RNA in human cells," nature biotechnology, Vol. 29:505-508 (2002)	
	C23	Scherr, Michaela, et al., "Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells,"  Current Medicinal Chemistry, Vol. 10:245-256 (2003)	
	C24	Sharp, Phillip A., "RNA interference - 2001," Genes & Development, Vol. 15:485-490 (2001)	
	C25	Spiller, David G., et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood, Vol.</i> 91(12):4738-4746 (1998)	
	C26	Sui, Guangchao, et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," PNAS, Vol. 99(8):515-5520 (2002)	
	C27	Summers, Scott A., et al., "Differentiation-dependent Suppression of Platelet-derived Growth Factor Signaling in Cultured Adipocytes," The Journal of Biological Chemistry, Vol. 274(34):23858-23867 (1999)	
	C28	Tuschl, Thomas, "Expanding small RNA interference," nature biotechnology, Vol. 20:446-448 (2002)	
	C29	Ueki, Kohjiro, et al., "Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis," <i>The Journal of Biological Chemistry</i> , Vol. 273(9);5315-5322 (1998)	
	C30	Wang, Qinghua, et al., "Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts," Molecular and Cellular Biology, Vol. 19(6):4008-4018 (1999)	
	C31	Williams, Michayla R., et al., "The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells," Current Biology, Vol. 10:439-448 (2000)	
	C32	Yu, Jenn-Yah, et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," PNAS, Vol. 99(9):6047-6052 (2002)	
RS	C33	Zeng, Yan, et al., "Both natural and Designated Micro RNAs Can Inhibit the Expression of Cognate mRNAs When Expressed in Human Cells," <i>Molecular Cell</i> , Vol. 9:1327-1333 (2002)	

\*EXAMINER: tritital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

-		<u> </u>	
Examiner Signature All	Date Considered	6/8/06	_